GHRP-2 vs Ipamorelin

Both are classed here as growth hormone secretagogues, so this is a within-class choice: the mechanism is broadly shared and what separates them is kinetics, route, and how much has actually been tested.

The overlap is recovery and sleep and muscle growth. On this site's goal weighting — an editorial priority score, not a measure of effect size — GHRP-2 rates 3/5 for recovery and sleep and Ipamorelin rates 4/5. Outside that overlap only GHRP-2 goes further, carrying weight for appetite control; Ipamorelin's declared goals stop at the overlap.

This is the part that decides most of it. GHRP-2 has approval from a regulator somewhere, though not a current FDA or EMA label — registered in Japan as pralmorelin for a single-dose diagnostic test, not chronic use. Ipamorelin has some human data, but it is small, old, or uncontrolled — small early-phase work only; development was discontinued. That gap is the headline, and it is a statement about the literature rather than a promise about you: a compound with trial data can still do nothing for your case, and one without it is unproven rather than disproven.

GHRP-2 is a subcutaneous injection and an intramuscular injection; Ipamorelin is a subcutaneous injection. Both are injected, so route does not decide this one.

Half-lives are close — 1 h for GHRP-2, 2 h for Ipamorelin — and both are dosed once daily, so the rhythm of actually running them is the same.

Ipamorelin is rated beginner here and GHRP-2 intermediate. That rating is about how much can go wrong in handling, dosing and monitoring, not about how well either works.